KaliVir Immunotherapeutics was founded in 2019 to pioneer a unique and novel approach to cancer treatment that engages a virus’ natural ability to replicate in and kill cancer cells. This modality is known as oncolytic viral immunotherapy. KaliVir’s cutting-edge, next generation oncolytic viral immunotherapy programs combine technologies developed in-house and licensed from University of Pittsburgh’s world-class oncolytic virus and immunotherapy research programs.
Company Details
- Employees
- 29
- Founded
- -
- Address
- 240 Alpha Dr, Pittsburgh,pennsylvania 15238,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://kalivir.com
- HQ
- Pittsburgh, Pennsylvania
Kalivir Immunotherapeutics Questions
Kalivir Immunotherapeutics's website is http://kalivir.com
Kalivir Immunotherapeutics's LinkedIn profile is https://www.linkedin.com/company/kalivir-immunotherapeutics
Kalivir Immunotherapeutics has
29 employees.
View email and phone details for 29
employees at Kalivir Immunotherapeutics.
Kalivir Immunotherapeutics's industry is
Biotechnology Research
Kalivir Immunotherapeutics's top competitors are
Cognition Therapeutics, Inc.,
Duo Oncology,
Avista Therapeutics,
Western Oncolytics Ltd.,
Bluesphere Bio,
Castle Biosciences, Inc.,
Myris Therapeutics,
Matica Biotechnology, Inc.,
Krystal Biotech, Inc.,
Noveome Biotherapeutics, Inc..
Kalivir Immunotherapeutics's categories are Biotechnology Research
Kalivir Immunotherapeutics's founding year is 2019
